Neoantigen-MHC-TCR complex (NeoAg-MHC-TCR)

The Neoantigen-MHC-TCR complex is the fundamental structural and functional unit of the immune synapse, mediating the recognition of malignant cells by the adaptive immune system. It comprises a patient-specific neoantigen—a peptide derived from a tumor-specific somatic mutation—presented by a Major Histocompatibility Complex (MHC) molecule and recognized by a cognate T-cell receptor (TCR) (Schumacher & Schreiber, 2015, Science). Unlike shared tumor-associated antigens, neoantigens are entirely absent from healthy tissues, allowing for high-precision targeting with minimal risk of central tolerance (Blass & Ott, 2021, Nature Reviews Clinical Oncology). The formation of this complex at the immune synapse triggers a signaling cascade that leads to T-cell activation, proliferation, and the targeted destruction of tumor cells via cytotoxic granules (Grakoui et al., 1999, Science). Therapeutic strategies exploiting this interaction include personalized mRNA vaccines (e.g., mRNA-4157) and adoptive cell therapies using TCR-engineered T cells (TCR-T) (Sahin et al., 2017, Nature). However, challenges such as tumor heterogeneity, HLA downregulation, and the risk of cross-reactivity with self-antigens remain significant hurdles in clinical development (Middleton et al., 2020, Journal for ImmunoTherapy of Cancer).

Other names

pMHC-TCR complexNeoantigen-specific T-cell receptor complexTumor-specific immune synapseNeoantigen-HLA-TCR interactionPeptide-MHC-TCR complex

Recognition of tumor-specific neoepitopes presented by MHC molecules by engineered or endogenous T-cell receptors, leading to the formation of a stable immune synapse and subsequent T-cell mediated lysis of the tumor cell.